Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy.

PubWeight™: 1.94‹?› | Rank: Top 3%

🔗 View Article (PMID 12789226)

Published in J Allergy Clin Immunol on June 01, 2003

Authors

James N Francis1, Stephen J Till, Stephen R Durham

Author Affiliations

1: Upper Respiratory Medicine, National Heart and Lung Institute, Imperial College, Dovehouse Street, London SW3 6LY, UK.

Articles citing this

CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J Exp Med (2005) 3.03

IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J Clin Invest (2006) 1.77

Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J Immunol (2010) 1.76

Tregs and allergic disease. J Clin Invest (2004) 1.64

Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells. J Immunol (2008) 1.58

Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol (2014) 1.49

Regulation of adaptive immunity; the role of interleukin-10. Front Immunol (2013) 1.38

Regulatory T cells in many flavors control asthma. Mucosal Immunol (2010) 1.28

T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med (2005) 1.24

Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol (2012) 1.18

Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov (2009) 1.10

T-cell subset regulation in atopy. Curr Allergy Asthma Rep (2011) 1.09

Update in the mechanisms of allergen-specific immunotheraphy. Allergy Asthma Immunol Res (2010) 1.07

Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. J Exp Med (2011) 1.06

An imbalance of esophageal effector and regulatory T cell subsets in experimental eosinophilic esophagitis in mice. Am J Physiol Gastrointest Liver Physiol (2009) 1.05

Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-β. Genes Immun (2014) 1.05

The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods (2006) 1.03

Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J (2009) 1.03

Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. J Clin Invest (2014) 1.03

Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J (2015) 1.03

Tracking antigen-specific T-cells during clinical tolerance induction in humans. PLoS One (2010) 0.99

In Vitro Induction of Allergen-Specific Interleukin-10-Producing Regulatory B Cell Responses by Interferon-γ in Non-Immunoglobulin E-Mediated Milk Allergy. Allergy Asthma Immunol Res (2012) 0.97

Phthalates, Pesticides, and Bisphenol-A Exposure and the Development of Nonoccupational Asthma and Allergies: How Valid Are the Links? Open Allergy J (2009) 0.97

T-cell responses induced by allergen-specific immunotherapy. Clin Exp Immunol (2010) 0.94

Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med (2009) 0.94

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol (2012) 0.93

Penaeus monodon tropomyosin induces CD4 T-cell proliferation in shrimp-allergic patients. Hum Immunol (2011) 0.88

Tolerizing allergic responses in the lung. Mucosal Immunol (2010) 0.88

Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses. Chest (2012) 0.88

Clinical immunology review series: an approach to desensitization. Clin Exp Immunol (2010) 0.85

Cross-reactivity in Grasses: Biochemical Attributes Define Exemplar Relevance. World Allergy Organ J (2012) 0.85

Proteolytically inactive per a 10 allergen of Periplaneta americana modulates Th2 response and enhances IL-10 in mouse model. J Clin Immunol (2010) 0.85

Regulation of type 1 diabetes, tuberculosis, and asthma by parasites. J Mol Med (Berl) (2009) 0.85

Retrospective Analysis on the Effects of House Dust Mite Specific Immunotherapy for More Than 3 Years in Atopic Dermatitis. Yonsei Med J (2016) 0.84

Synergistic effect of various regulatory factors in TH1/TH2 balance; immunotherapeutic approaches in asthma. Int J Biomed Sci (2008) 0.84

Type 2 immune-inducing helminth vaccination maintains protective efficacy in the setting of repeated parasite exposures. Vaccine (2009) 0.83

Immunological mechanisms for desensitization and tolerance in food allergy. Semin Immunopathol (2012) 0.83

Immunotherapy with allergen peptides. Allergy Asthma Clin Immunol (2007) 0.83

Regulatory activity of human CD4 CD25 T cells depends on allergen concentration, type of allergen and atopy status of the donor. Immunology (2005) 0.83

Successful immunotherapy induces previously unidentified allergen-specific CD4+ T-cell subsets. Proc Natl Acad Sci U S A (2016) 0.82

Adjuvants for allergy vaccines. Hum Vaccin Immunother (2012) 0.82

Glycogen synthase kinase-3 controls IL-10 expression in CD4(+) effector T-cell subsets through epigenetic modification of the IL-10 promoter. Eur J Immunol (2015) 0.82

Daily subcutaneous injections of peptide induce CD4+ CD25+ T regulatory cells. Clin Exp Immunol (2007) 0.81

T-cell biology in immunotherapy. Ann Allergy Asthma Immunol (2014) 0.80

The role of regulatory T cells in allergy. Springer Semin Immunopathol (2003) 0.80

Tolerogenic dendritic cells derived from donors with natural rubber latex allergy modulate allergen-specific T-cell responses and IgE production. PLoS One (2014) 0.80

Characterisation of CD154+ T cells following ex vivo birch allergen stimulation defines a close relationship between T cell subsets in healthy volunteers. BMC Immunol (2013) 0.80

Strategies to query and display allergy-derived epitope data from the immune epitope database. Int Arch Allergy Immunol (2012) 0.80

Bystander immunotherapy as a strategy to control allergen-driven airway inflammation. Mucosal Immunol (2014) 0.79

Specific immunotherapy to birch allergen does not enhance suppression of Th2 cells by CD4(+)CD25(+) regulatory T cells during pollen season. J Clin Immunol (2009) 0.79

Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin Immunother (2012) 0.79

CD4-blockade can induce protection from peanut-induced anaphylaxis. Front Immunol (2011) 0.79

Peptide immunotherapy for childhood allergy - addressing translational challenges. Clin Transl Allergy (2011) 0.78

Evaluation of clinical and immunological responses: a 2-year follow-up study in children with allergic rhinitis due to house dust mite. Mediators Inflamm (2013) 0.78

Allergen-specific subcutaneous immunotherapy in allergic asthma: immunologic mechanisms and improvement. Libyan J Med (2010) 0.78

Effects of omalizumab on T lymphocyte function in inner-city children with asthma. Pediatr Allergy Immunol (2016) 0.78

Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE). Clin Transl Allergy (2013) 0.77

Persistence and evolution of allergen-specific IgE repertoires during subcutaneous specific immunotherapy. J Allergy Clin Immunol (2015) 0.77

Correlation of Local FOXP3-Expressing T Cells and Th1-Th2 Balance in Perennial Allergic Nasal Mucosa. Int J Otolaryngol (2011) 0.77

Current immunological approaches for management of allergic rhinitis and bronchial asthma. Inflamm Res (2009) 0.77

Ablation of ovomucoid-induced allergic response by desensitization with recombinant ovomucoid third domain in a murine model. Clin Exp Immunol (2006) 0.77

Use of multiple peptides containing T cell epitopes is a feasible approach for peptide-based immunotherapy in Can f 1 allergy. Immunology (2007) 0.77

New strategies for allergen T cell epitope identification: going beyond IgE. Int Arch Allergy Immunol (2014) 0.76

Differential gene network analysis for the identification of asthma-associated therapeutic targets in allergen-specific T-helper memory responses. BMC Med Genomics (2016) 0.76

Novel developments in the mechanisms of immune tolerance to allergens. Hum Vaccin Immunother (2012) 0.76

The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children. Allergy Asthma Clin Immunol (2014) 0.76

[Allergen-specific Immunotherapy for children and adolescents - a review on available products in Austria]. Wien Klin Wochenschr (2009) 0.76

Immunotherapy in all aspects. Eur Arch Otorhinolaryngol (2015) 0.76

Induction of IL-10 cytokine and the suppression of T cell proliferation by specific peptides from red cell band 3 and in vivo effects of these peptides on autoimmune hemolytic anemia in NZB mice. Auto Immun Highlights (2017) 0.75

Critical appraisal of Timothy grass pollen extract GRAZAX(®) in the management of allergic rhinitis. Drug Des Devel Ther (2015) 0.75

Update on allergy immunotherapy. Allergy Asthma Clin Immunol (2005) 0.75

Basic science for the clinician: Mechanisms of sublingual and subcutaneous immunotherapy. Ann Allergy Asthma Immunol (2016) 0.75

Short-term intratracheal use of PEG-modified IL-2 and glucocorticoid persistently alleviates asthma in a mouse model. Sci Rep (2016) 0.75

The interleukin-10 inducing effect of transforming growth factor-beta on human naive CD4+ T cells from cord blood is restricted to the TH1 subset. Clin Exp Immunol (2007) 0.75

Clinical practice: Allergen-specific immunotherapy in children: facts and FAQs. Eur J Pediatr (2010) 0.75

Sublingual immunotherapy (SLIT) for house dust mites does not prevent new allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis children. PLoS One (2017) 0.75

Articles by these authors

Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest (2009) 4.10

Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol (2004) 2.40

Ethnic variations in UK asthma frequency, morbidity, and health-service use: a systematic review and meta-analysis. Lancet (2005) 2.07

Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol (2003) 2.01

Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.87

Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol (2007) 1.85

Is occupational asthma to diisocyanates a non-IgE-mediated disease? J Allergy Clin Immunol (2006) 1.68

Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy (2009) 1.65

Tregs and allergic disease. J Clin Invest (2004) 1.64

Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol (2011) 1.62

Mechanisms of immunotherapy. J Allergy Clin Immunol (2004) 1.45

Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol (2008) 1.43

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol (2008) 1.38

Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol (2013) 1.33

Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol (2005) 1.30

Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol (2007) 1.28

Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol (2010) 1.27

Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol (2004) 1.26

Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.26

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol (2007) 1.22

Regulatory T cells and allergic disease. Inflamm Allergy Drug Targets (2008) 1.15

The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol (2003) 1.13

Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol (2007) 1.12

Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol (2005) 1.12

Mucosal immunity in asthma and chronic obstructive pulmonary disease: a role for immunoglobulin A? Proc Am Thorac Soc (2004) 1.09

Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy (2003) 1.08

Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol (2012) 1.08

Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy. J Allergy Clin Immunol (2012) 1.08

Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol (2007) 1.06

EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy (2012) 1.04

Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods (2012) 1.04

The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods (2006) 1.03

Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J (2009) 1.03

A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J Immunol (2013) 1.02

Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol (2011) 1.02

Local somatic hypermutation and class switch recombination in the nasal mucosa of allergic rhinitis patients. J Immunol (2003) 1.02

IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol (2005) 1.01

Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology (2002) 1.00

Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol (2003) 0.99

CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol (2002) 0.99

Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol (2004) 0.98

Functional endoscopic sinus surgery: 5 year follow up and results of a prospective, randomised, stratified, double-blind, placebo controlled study of postoperative fluticasone propionate aqueous nasal spray. Rhinology (2005) 0.98

IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy. Immunol Allergy Clin North Am (2006) 0.97

IL-22 suppresses IFN-γ-mediated lung inflammation in asthmatic patients. J Allergy Clin Immunol (2012) 0.96

Germinal-centre reactions in allergic inflammation. Trends Immunol (2006) 0.95

Allergen immunotherapy and tolerance. Allergol Int (2013) 0.92

NHS allergy services in the UK: proposals to improve allergy care. Clin Med (2002) 0.91

One hundred years of allergen immunotherapy: time to ring the changes. J Allergy Clin Immunol (2011) 0.90

Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther (2013) 0.90

Biased use of VH5 IgE-positive B cells in the nasal mucosa in allergic rhinitis. J Allergy Clin Immunol (2005) 0.89

An extreme consequence of splenectomy in dehydrated hereditary stomatocytosis: gradual thrombo-embolic pulmonary hypertension and lung-heart transplantation. Hemoglobin (2003) 0.88

Serum immunologic markers for monitoring allergen-specific immunotherapy. Immunol Allergy Clin North Am (2011) 0.88

Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol (2004) 0.87

Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics. Am J Respir Crit Care Med (2002) 0.86

Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res (2006) 0.85

The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol (2010) 0.84

Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. Thorax (2013) 0.83

CXCR1+CD4+ T cells in human allergic disease. J Immunol (2004) 0.83

Postnasal drip and chronic cough: An open interventional study. Respir Med (2009) 0.82

Tobacco industry lobbyists and their health-care clients. Lancet (2013) 0.82

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. J Allergy Clin Immunol (2012) 0.82

Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE. J Allergy Clin Immunol (2012) 0.81

Mechanisms of sublingual immunotherapy. Immunol Allergy Clin North Am (2011) 0.81

Immunological responses to allergen immunotherapy. Clin Allergy Immunol (2004) 0.81

Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. J Allergy Clin Immunol (2013) 0.80

Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin Immunother (2012) 0.79

Local IgE synthesis in allergic rhinitis and asthma. Curr Allergy Asthma Rep (2002) 0.78

Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE). Clin Transl Allergy (2013) 0.77

Rhinitis with negative skin tests and absent serum allergen-specific IgE: more evidence for local IgE? J Allergy Clin Immunol (2009) 0.77

Sublingual immunotherapy for allergic Rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. Clin Allergy Immunol (2008) 0.76

Immunomodulatory treatment strategies for allergic diseases. Curr Drug Targets Inflamm Allergy (2003) 0.76

Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respir Med (2006) 0.75

Perennial rhinitis. BMJ (2007) 0.75

Treatment of seasonal allergic rhinitis: desensitisation for hay fever works. BMJ (2003) 0.75

Silk contact anaphylaxis. Contact Dermatitis (2014) 0.75

Biomarkers of tolerance in response to allergen immunotherapy. Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess (2013) 0.75

Allergen injection immunotherapy. Clin Allergy Immunol (2002) 0.75

Immunologic responses to subcutaneous allergen immunotherapy. Clin Allergy Immunol (2008) 0.75

Tradition and innovation: finding the right balance. J Allergy Clin Immunol (2007) 0.75